Ability to give written informed consent to the study
Age range 18-65 years
Diagnosis of primary of secondary progressive MS according to 2017 revised Macdonald's criteria (Thompson et al., 2017), presenting with signs of symptoms of progressive dysfunction of the corticospinal tract
EDSS ≤ 6,5
Ability to participate to the study protocol
No or stable (at least six months) DMT or rehabilitative treatments before study entry, and willingness not to change these therapies (including cannabinoids, SSRI, baclofen) during the study.
You may not be if
Relapsing-remitting MS or progressive MS presenting with signs of symptoms other than those typical of the ascending myelopathy phenotype (i.e. progressive cerebellar or cognitive involvement)
Female with positive pregnancy test at baseline or having active pregnancy plans
Comorbidities for which synaptic plasticity may be altered (i.e., Parkinson's disease, Alzheimer's disease, stroke)
Contraindications to TMS
History or presence of any unstable medical condition such as malignancy or infection
Use of medications with increased risk of seizures (i.e. Fampridine, 4-Aminopyridine)
Concomitant use of drugs that may alter synaptic transmission and plasticity (L-dopa, antiepileptics)
Clareo Health | Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
